Nvp tae226

Manufactured by Novartis

NVP-TAE226 is a laboratory equipment product manufactured by Novartis. It is a small molecule that targets and inhibits the autophosphorylation of Focal Adhesion Kinase (FAK). This core function is used for research purposes.

Automatically generated - may contain errors

Lab products found in correlation

Dimethyl sulfoxide (dmso), by Merck Group (1 mentions) Zd1839, by AstraZeneca (1 mentions) Torin1, by Bio-Techne (1 mentions) Rapamycin, by Merck Group (1 mentions) Palomid 529, by Selleck Chemicals (1 mentions) Rad001, by Selleck Chemicals (1 mentions) Bkm120, by Active Motif (1 mentions) Ink128, by Active Motif (1 mentions) Azd8055, by Selleck Chemicals (1 mentions) Mk 2206, by Selleck Chemicals (1 mentions) Mg132, by Selleck Chemicals (1 mentions)

2 protocols using nvp tae226

Preparation of NVP-TAE226 and ZD1839

Check if the same lab product or an alternative is used in the 5 most similar protocols

NVP-TAE226 was kindly provided by Novartis Pharma AG (Basel, Switzerland). ZD1839 (gefitinib) was kindly provided by AstraZeneca (Wilmington, DE). The stock solution of these compounds was respectively reconstituted in the concentration of 20 mM and 10 mM with dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) and stored at -20°C until used for in vitro experiments.

Otani H., Yamamoto H., Takaoka M., Sakaguchi M., Soh J., Jida M., Ueno T., Kubo T., Asano H., Tsukuda K., Kiura K., Hatakeyama S., Kawahara E., Naomoto Y., Miyoshi S, & Toyooka S. (2015). TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS ONE, 10(6), e0129838.

+ Open protocol

+ Expand

Investigating AKT and mTOR Inhibitors in Cancer Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were seeded onto collagen IV-coated coverslips, allowed to attach overnight, and treated with vehicle (DMSO) or AKT1/2 inhibitor (HCT116: 20μM; MCF7: 2μM) (Sigma), MK2206 (HCT116: 10μM; MCF7: 3μM) (Selleck Chemicals), TORIN1 (HCT116: 0.5μM; MCF7: 0.25μM) (Tocris Bioscience), AZD8055 (HCT116: 0.7μM; MCF7: 0.1μM) (Selleck Chemicals), INK128 (HCT116: 0.05μM; MCF7: 0.01μM) (Active Biochem), Palomid 529 (HCT116: 10μM; MCF7: 20μM) (Selleck Chemicals), (Rapamycin (HCT116: 20μM; MCF7: 20μM) (Sigma), RAD-001 (HCT116: 10μM; MCF7: 5μM) (Selleck Chemicals), BKM-120 (HCT116: 1.5μM; MCF7: 0.5μM) (Active Biochem), FAK inhibitors (PF-562271: 1μM (Pfizer) and NVP-TAE226 : 1μM (Novartis), for both cell lines) for 72 hours or 144 hours and Bortezemib (HCT116: 1μM; MCF7: 4μM) (Selleck Chemicals) MG-132 (vehicle: ethanol) (HCT116: 1μM; MCF7: 10μM), for 24 hours.

Dey-Guha I., Alves C.P., Yeh A.C., S.a.l.o.n.y., Sole X., Darp R, & Ramaswamy S. (2015). A MECHANISM FOR ASYMMETRIC CELL DIVISION RESULTING IN PROLIFERATIVE ASYNCHRONICITY. Molecular cancer research : MCR, 13(2), 223-230.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!